Clinical evaluation of CENP-B and Scl-70 autoantibodies in silicosis patients

Silicosis patients (SIL) suffer from respiratory disorders and dysregulation of autoimmunity. Frequent complications such as rheumatoid arthritis, systemic sclerosis (SSc) and vasculitis are known in SIL. Furthermore, we reported previously that some SIL exhibited better respiratory conditions in association with a worse immunological status. In this study, the clinical roles of anti-CENP-B and Scl-70 autoantibodies in SIL were analyzed. The titer index (Log10) of anti-CENP-B autoantibody in SIL was higher than that of healthy volunteers (HV), and that of SSc was higher than those of HV and SIL. This titer index was positively correlated with an assumed immune status of 1 for HV, 2 for SIL, and 3 for SSc. Moreover, although factor analysis revealed that the titer index of the anti-CENP-B autoantibody formed the same factor with the anti-Scl-70 autoantibody, IgG value and age in SIL cases, another extracted factor indicated that the IgA value and anti-Scl-70 antibody were positively related, but anti-CENP-B showed an opposite pattern in the results of the factor analysis. These findings indicated that the titer index of anti-CENP-B autoantibody may be a biomarker for dysregulation in SIL cases. Future clinical follow-up of SIL may therefore require both respiratory and immunological assessment.

[1]  H. Matsuzaki,et al.  Environmental factors and human health: fibrous and particulate substance-induced immunological disorders and construction of a health-promoting living environment , 2016, Environmental Health and Preventive Medicine.

[2]  A. Fazaa,et al.  Association of pulmonary silicosis and systemic sclerosis , 2015, BMJ Case Reports.

[3]  Ying Chen,et al.  Silica exposure and altered regulation of autoimmunity , 2014, Environmental Health and Preventive Medicine.

[4]  N. Amft,et al.  Systemic lupus erythematosus complicating simple silicosis. , 2014, Occupational medicine.

[5]  Y. Shoenfeld,et al.  Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. , 2013, Journal of autoimmunity.

[6]  Y. Shoenfeld,et al.  Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum , 2013, Expert review of clinical immunology.

[7]  W. Fujimoto,et al.  Environmental factors producing autoimmune dysregulation--chronic activation of T cells caused by silica exposure. , 2012, Immunobiology.

[8]  T. Otsuki,et al.  Dysregulation of the immune system caused by silica and asbestos , 2010, Journal of immunotoxicology.

[9]  S. Murakami,et al.  Reductive Alteration of the Regulatory Function of the CD4+CD25+ T Cell Fraction in Silicosis Patients , 2010, International journal of immunopathology and pharmacology.

[10]  S. Murakami,et al.  Soluble Interleukin-2 Receptor as an Indicator of Immunological Disturbance Found in Silicosis Patients , 2009, International journal of immunopathology and pharmacology.

[11]  T. Nakano,et al.  Immunological effects of silica and asbestos. , 2007, Cellular & molecular immunology.

[12]  D Rees,et al.  Silica, silicosis and tuberculosis. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  H. Nishimura,et al.  Silica-associated systemic lupus erythematosus in an elderly man. , 2007, Internal medicine.

[14]  A. Ueki,et al.  Alterations of Fas and Fas-Related Molecules in Patients with Silicosis , 2006, Experimental biology and medicine.

[15]  H. Sakaguchi,et al.  Reduced Function of CD4+25+ Regulatory T Cell Fraction in Silicosis Patients , 2006, International journal of immunopathology and pharmacology.

[16]  W. Fujimoto,et al.  Detection, epitope‐mapping and function of anti‐Fas autoantibody in patients with silicosis , 2005, Immunology.

[17]  W. Rom,et al.  Basic pathogenetic mechanisms in silicosis: current understanding , 2005, Current opinion in pulmonary medicine.

[18]  J. Reveille,et al.  Anti-scl-70 , 2005, Autoimmunity.

[19]  T. Saeki,et al.  Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive pulmonary silicosis in tunnel workers , 2004, Clinical Rheumatology.

[20]  P. Itin,et al.  Arthritis and interstitial granulomatous dermatitis (Ackerman syndrome) with pulmonary silicosis. , 2003, Seminars in arthritis and rheumatism.

[21]  Y. Isozaki,et al.  Intramolecular epitope spreading among anti‐caspase‐8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals , 2002, Clinical and experimental immunology.

[22]  H. Sakaguchi,et al.  Autoantibodies detectable in the sera of silicosis patients. The relationship between the anti-topoisomerase I antibody response and HLA-DQB1*0402 allele in Japanese silicosis patients. , 2001, The Science of the total environment.

[23]  A. Ueki,et al.  Antidesmoglein Autoantibodies in Silicosis Patients with No Bullous Diseases , 2001, Dermatology.

[24]  H. Sakaguchi,et al.  Is the anti-topoisomerase I autoantibody response associated with a distinct amino acid sequence in the HLA-DQbeta1 domain? , 2001, Arthritis and rheumatism.

[25]  H. Sakaguchi,et al.  Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain. , 2001, Immunobiology.

[26]  H. Sakaguchi,et al.  Reduced Expression of the Inhibitory Genes for Fas‐Mediated Apoptosis in Silicosis Patients , 2000 .

[27]  H. Sakaguchi,et al.  Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. , 2000, Immunology letters.

[28]  Otsuki,et al.  Over‐expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients , 2000, Clinical and experimental immunology.

[29]  H. Sakaguchi,et al.  Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis. , 1999, International journal of molecular medicine.

[30]  G. Cooper,et al.  Occupational exposure to crystalline silica and autoimmune disease. , 1999, Environmental health perspectives.

[31]  C. Kallenberg,et al.  Silicon exposure and vasculitis. , 1998, Current opinion in rheumatology.

[32]  Y. Isozaki,et al.  Elevated soluble Fas/APO‐1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours , 1997, Clinical and experimental immunology.

[33]  K. Steenland,et al.  Silica exposure and autoimmune diseases. , 1995, American journal of industrial medicine.

[34]  T. Dragani,et al.  Libri Ricevuti: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1992 .

[35]  C. Kallenberg,et al.  Early detection of connective tissue disease in patients with Raynaud's phenomenon. , 1990, Rheumatic diseases clinics of North America.

[36]  P. Hessel,et al.  Silica, silicosis, and progressive systemic sclerosis. , 1985, British journal of industrial medicine.

[37]  R. A. McReynolds,et al.  Immunotoxicology of silica. , 1982, Critical reviews in toxicology.

[38]  K. Constantinidis.  Pneumoconiosis and Rheumatoid arthritis (Caplan's syndrome). , 1977, The British journal of clinical practice.

[39]  T. Benedek.  Rheumatoid pneumoconiosis. Documentation of onset and pathogenic considerations. , 1973, The American journal of medicine.

[40]  P. Elmes,et al.  International classification of radiographs of pneumoconioses. , 1971, British journal of industrial medicine.

[41]  T. Medsger,et al.  The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis. , 1967, Annals of internal medicine.

[42]  A. Caplan.  Rheumatoid Disease and Pneumoconiosis (Caplan's Syndrome) , 1959, Proceedings of the Royal Society of Medicine.